ReviewEBioMedicine2022
Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
Review in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Immune mechanisms mediating the heterologous effects of BCG vaccination: a systematic review.Frontiers in immunology · 2025Pooled it
- Exploring the ethics of tuberculosis human challenge models.Journal of medical ethics · 2026Article
- A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026Article
- Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant.ImmunoHorizons · 2025Article
- The frequency of CD38Nature communications · 2024Article
- Cachexia in tuberculosis in South-East Asian and African regions: knowledge gaps and untapped opportunities.Annals of medicine and surgery (2012) · 2024Review
- CD38+ Alveolar macrophages mediate early control of M. tuberculosis proliferation in the lung.Research square · 2024Article
- Review
- Ending tuberculosis: challenges and opportunities.Frontiers in tuberculosis · 2024Review
- Key advances in vaccine development for tuberculosis-success and challenges.NPJ vaccines · 2023Review
- ESAT-6 a Major Virulence Factor ofBiomolecules · 2023Review
- Article
- Planning to introduce novel tuberculosis vaccines in high burden settings: how could this be done?The Lancet. Global health · 2023Article
- Impact of COVID-19 Pandemic on Tuberculosis Preventive Services and Their Post-Pandemic Recovery Strategies: A Rapid Review of Literature.Journal of Korean medical science · 2023Review
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments.Nanomedicine : nanotechnology, biology, and medicine · 2023Review
- Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges.Pharmaceutics · 2023Review
- A feasibility study of controlled human infection with intradermal Bacillus Calmette-Guérin (BCG) injection: Pilot BCG controlled human infection model.Wellcome open research · 2023Article
- Malnutrition vaccines for an imminent global food catastrophe.Trends in pharmacological sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.